Literature DB >> 22746356

Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records.

Marc B Rosenman1, Layla Baker, Yonghua Jing, Dinara Makenbaeva, Brian Meissner, Teresa A Simon, Daniel Wiederkehr, Steve Deitelzweig.   

Abstract

OBJECTIVE: Automated electronic queries of structured data fields in electronic medical records (EMR) found no barriers to warfarin in 42% of patients with atrial fibrillation or atrial flutter (AF) with moderate or high risk of stroke and no warfarin. A thorough manual review of records (including text reports) from the same EMR may better identify physicians' reasons for not using warfarin.
METHODS: This was a cross-sectional, retrospective, manual EMR review. Patients identified in a previous automated EMR study with a CHADS2 (Chronic heart failure, Hypertension, Age >75 years, Diabetes mellitus, Stroke) score≥2, no record of warfarin, no barrier to warfarin use, and (in the present study) confirmation of AF diagnosis were included in the manual EMR review. A structured chart abstraction form was used to extract data visible in the clinicians' EMR user interface. Reasons why warfarin had not been prescribed were reported using descriptive statistics.
RESULTS: Among 408 patients with 'no barriers' to warfarin in the automated EMR review, AF diagnosis was confirmed in 319 patients (mean age 74.8; 65% female). Forty-one percent (n=132) did not have chart records explaining why they were not on warfarin. Among the 59% (187) with a rationale against warfarin found in the records, the most common category (52%) was indicative of the risk of bleeding, either risk of fall or history of recent bleeding. The second most common category (16%) reflected that the patient was back in sinus rhythm. These findings are subject to inherent limitations of retrospective chart reviews.
CONCLUSIONS: Many patients with AF and moderate-to-high risk of stroke are not treated with warfarin, and reasons for not using warfarin could not always be identified in patient records. Among patients with documented reasons, risk of bleeding (risk of fall or recent bleeding) was the most common category.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22746356     DOI: 10.1185/03007995.2012.708653

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  10 in total

1.  The role of contraindications in prescribing anticoagulants to patients with atrial fibrillation: a cross-sectional analysis of primary care data in the UK.

Authors:  Nicola Adderley; Ronan Ryan; Tom Marshall
Journal:  Br J Gen Pract       Date:  2017-06-19       Impact factor: 5.386

2.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2013

Review 3.  Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

4.  Poor adherence to anticoagulation guidelines in patients with non-valvular atrial fibrillation treated in a tertiary cardiology unit.

Authors:  Guan Sen Kew; Mabel Tan; Toon Wei Lim
Journal:  Heart Asia       Date:  2015-04-21

Review 5.  Minimizing the Risk of Bleeding with NOACs in the Elderly.

Authors:  Amartya Kundu; Partha Sardar; Saurav Chatterjee; Wilbert S Aronow; Theophilus Owan; John J Ryan
Journal:  Drugs Aging       Date:  2016-07       Impact factor: 3.923

Review 6.  Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence.

Authors:  Arthur Bracey; Wassim Shatila; James Wilson
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-09-30

7.  Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation.

Authors:  Fatima Khan; Hans Huang; Yvonne H Datta
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

8.  Traumatic fatal cerebral hemorrhage in an old patient with a history of multiple sclerosis under dabigatran: a case report and review of the literature.

Authors:  Claudia Stöllberger; Andreas Ulram; Adam Bastovansky; Josef Finsterer
Journal:  J Geriatr Cardiol       Date:  2015-01       Impact factor: 3.327

9.  Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?

Authors:  Yi-Pin Lin; Teng-Yeow Tan
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

Review 10.  Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective.

Authors:  Carlos Cantú-Brito; Gisele Sampaio Silva; Sebastián F Ameriso
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-09       Impact factor: 2.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.